HEALEY ALS Platform Trial Webinar: February 26, 2026 | Neurofilament Analysis

James Berry, MD, MPH, and biostatistician Jenny Wang, MS, PhD, of Massachusetts General Hospital led a discussion titled “Understanding Neurofilament (NfL) in ALS: What it tells us and how it is used in clinical trials”. The presenters looked at NfL as a prognostic biomarker and dynamic trial endpoint in ALS research, citing real-world examples such as NfL analyses conducted using data from the HEALEY ALS Platform Trial. Visit the Mass General website to register for future Platform Trial webinars: https://www.massgeneral.org/neurology... Sign up for the ALS Link to stay up to date about news and research from the Sean M. Healey & AMG Center for ALS: https://lp.constantcontactpages.com/s... Follow MGH Neurology on Facebook (  / mghneurology  ) and X (https://x.com/MGHNeurology)